Company: TVRD
Filing Date: 2025-01-21
Form Type: 8-K
Source: 0001104659-25-004747
Chunk: 0

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-21
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

As previously disclosed, on December 17, 2024,
Cara Therapeutics, Inc., a Delaware corporation (the “ Company”), entered into an Agreement and Plan of Merger and Reorganization
with Tvardi Therapeutics, Inc., a Delaware corporation (“ Tvardi”), a clinical-stage biopharmaceutical company focused on the
development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need, and
CT Convergence Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“ Merger Sub”), pursuant
to which Merger Sub will be merged with and into Tvardi, with Tvardi surviving as a wholly-owned subsidiary of the Company (the “ Merger”).

Attached hereto as Exhibit 99.1 and incorporated
by reference into this Item 7.01 is an investor presentation that will be shared with potential investors into Tvardi and the post-combination
company with respect to the Merger.

The information disclosed under this Item 7.01,
including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, nor shall they be incorporated by reference into any registration statement or other document pursuant
to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Cautionary Statement Regarding Forward-Looking
Statements